目的 发生于前列腺的恶性淋巴瘤较为少见.此前,中国人群前列腺恶性淋巴瘤的数据仅限于病例报告,因此对这类疾病的临床特征了解不甚全面.方法 本研究对1983年至2019年间发表的文章进行了系统检索和综述,旨在明确中国人群前列腺恶性淋巴瘤的临床特征和治疗效果.结果 研究队列中,原发性前列腺淋巴瘤占75％,大多数患者表现为Ⅰ期疾病(67％),侵袭性淋巴瘤(弥漫性大B细胞淋巴瘤为主)占73％.其中23％选择了R-CHOP(Rituximab-Cyclophosphamide,Hydroxydaunomycin,Oncovin,Prednisone)化疗方案,26％选择了 CHOP 化疗方案,6％选择了放疗或放化疗联合方案,23％的患者选择了其他化疗方案;其中有60％的患者选择了手术治疗以解除梗阻症状.该队列患者半年和一年累积生存率分别为70.7％和54.8％,接受治疗的患者半年和一年累积生存率分别为76.5％和56.5％.提示中国人群前列腺恶性淋巴瘤具有独特的组织病理学和临床特征.结论 近年来,随着淋巴瘤分类的不断标准化及新药的应用,淋巴瘤患者生存期显著延长.原发或继发性的前列腺淋巴瘤仍属于淋巴造血系统恶性肿瘤.应在解除下尿路梗阻等症状的同时,获取足够的组织明确病理亚型,参照最新的淋巴造血系统肿瘤的分类和诊治方案进行诊疗,以期达到最佳治疗效果.
Clinical features and treatment options of prostatic lymphoma in the Chinese population:a systematic review
Objective Malignant lymphomas occurring in the prostate are relatively rare.Previously,data on prostate malignant lymphoma in the Chinese population were limited to case reports,leading to an incomplete understanding of the clinical characteristics of this disease.Methods This study conducted a systematic search and review of articles published from 1983 to 2019.The aim was to clarify the clinical features and treatment outcomes of prostate malignant lymphoma in the Chinese population.Results In this cohort,primary prostate lymphoma accounted for 75％,most patients presented with stage Ⅰ disease(67％),and aggressive lymphoma(mainly diffuse large B-cell lymphoma)accounted for 73％.Among them,23％of patients chose R-CHOP(Rituximab-Cyclophosphamide,Hydroxydaunomycin,Oncovin,Prednisone)chemotherapy,26％of patients chose CHOP chemotherapy,6％of patients chose radiotherapy or a combination of radiotherapy and chemotherapy,23％of patients chose other chemotherapy;in whom 60％of patients chose surgery to relieve the obstructive symptoms.The half-year and one-year cumulative survival rates of the patients in this cohort were 70.7％and 54.8％,respectively,and the half-year and one-year cumulative survival rates of the treated patients were 76.5％and 56.5％,respectively.Conclusion In recent years,with the ongoing standardization of lymphoma classification and the application of new drugs,there has been a significant extension in the survival of patients with lymphoma.Lymphomas that originate in or spread to the prostate remain a form of malignancy within the lympho-hematopoietic system.It is essential to alleviate symptoms such as lower urinary tract obstructions while obtaining sufficient tissue to confirm the pathological subtype.This approach should be aligned with the latest classifications and treatment protocols for lympho-hematopoietic system tumors,aiming to achieve optimal therapeutic outcomes.
Chinese populationprostatelymphomatherapyprognosis
NETL
NSTL
万方数据
